Business
Hemostemix Adds the Treatment of Refractory Angina to Its Phase 1 Basket Protocol
Calgary, Alberta--(Newsfile Corp. - October 15, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTX...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Adds the Treatment of Refractory Angina to Its Phase 1 Basket ProtocolCalgary, Alberta--(Newsfile Corp. - October 15, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to announce that it has completed the drafting of its clinical trial protocol titled \"Treatment of Refractory Angina with Angiogenic Cell Precursors (ACP-01)\". The second protocol for its basket Phase 1 clinical trial, the protocol advances Hemostemix's regenerative-cardiology program toward addressing patients who suffer persistent chest pain despite maximal medical and surgical therapy.Plain-language summary:Hemostemix will officially apply for ethics approval to begin a new clinical trial testing its ACP-01 stem-cell therapy in people with severe chest pain (angina) who no longer responds to standard drugs or surgery. This marks the next step in bringing a new option to patients who live with constant, disabling heart pain.Significance of the FilingScientific paragraph:Angina pectoris — chest pain from insufficient blood supply to the heart - is a major symptom of ischemic heart disease and affects roughly five percent of adults over 40 in developed countries (Rinaldi 2025; Vos 2020). Refractory angina, defined as angina that persists despite optimal therapy, causes marked reductions in quality of life and functional capacity, frequent emergency visits, and substantial healthcare costs (Fox 2020; Manolis 2019). Although one-year mortality is only about four percent, many patients live with disabling pain due to limited revascularization options. Current management focuses on symptom relief rather than cure.Plain-language summary:Angina happens when the heart doesn't get enough blood. For many people, medicine or bypass surgery helps, but some continue to have severe chest pain every day. These patients often cannot work, exercise, or even sleep comfortably. Hemostemix's trial targets this group, offering hope where conventional treatments have failed.Scientif...